Fig. 7From: Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancerS145 phosphorylation of transgelin-2 predicts poor prognosis in patients with PDAC. a. Representative images of PDAC tissue stained with anti-phospho-S145-transgelin-2 (p-T2-S145) antibody. b. Survival analysis of PDAC patients according to level of anti-phospho-S145-transgelin-2. Dotted lines indicate the median survival time for each groupBack to article page